Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 1.044,76 € (+18,39 %). Medianen er 1.042,89 € (+18,17 %).
| Køb |
32 |
| Behold |
4 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
arGEN-X achieves strong revenue growth with Vyvgart, misses operating profit expectations
In the third quarter, group revenue at arGEN-X rose to $1.72 billion thanks to the drug Vyvgart, but operating income of $486 million was below analysts' expectations of $551 million. Net income attributable to shareholders amounted to $506 million; the result was weighed down in part by higher research and marketing costs. The company announced a label expansion for Vyvgart Hytrulo and another regulatory‑relevant study for dermatomyositis. » Mere på finanzen.net
arGEN-X grows strongly thanks to Vyvgart, but misses profit expectations
In the third quarter arGEN-X's revenue rose by more than half to $1.72 billion, almost entirely driven by the drug Vyvgart. Operating income climbed 40% to $486 million, but fell short of analysts' expectation of around $551 million. Higher research and marketing costs weighed on profitability; net income attributable to shareholders was $506 million (previous year $344 million). The stock fell in Brussels by up to about 2.6%. » Mere på finanzen.net
arGEN-X halts phase-III study of Efgartigimod Sc after negative interim analysis
arGEN-X has discontinued the advanced phase-III study of Efgartigimod Sc for the treatment of Sjögren’s syndrome after an interim analysis showed the main study endpoint could not be reached. The share price fell sharply at times, dropping about 9 percent in Tradegate trading to roughly €750. The company currently generates almost all of its revenue from Efgartigimod Alfa for myasthenia gravis and is seeking additional growth sources. At the same time, arGEN-X reported positive phase-II results for candidate FB102 in celiac disease and plans to move it into phase III. » Mere på finanzen.net
UBS upgrades arGEN-X to buy and raises price target to $1,400
UBS has upgraded arGEN‑X from “neutral” to “buy” and increased its price target from $960 to $1,400. Analyst Xian Deng calls the antibody specialist a “rare, highly successful growth story” and sees about $20 billion in revenue potential for the drug Vyvgart. The platform technology is expected to reduce reliance on Vyvgart; the stock at one point traded roughly 2.98% higher at €905.40. » Mere på finanzen.net
Argenx rise toward record high after successful phase‑III trial of Vyvgart
Argenx shares jumped sharply after positive approval data for Vyvgart and reached their highest level since late July in early trading, most recently up 8.2% at €790. The phase‑III study in immune‑mediated necrotizing myopathy (IMNM) met its primary endpoint. Analysts view the data very positively and see blockbuster potential for Vyvgart; UBS cited a possible peak annual revenue of up to $5 billion in its forecasts. With the price rise the stock is roughly 10% higher in 2026 and has more than multiplied over the past five years. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 1,52 mia. | - |
| Bruttofortjeneste | 1,37 mia. | - |
| Nettoresultat | 446,72 mio. | - |
| EBITDA | 475,86 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 54,44 mia. € |
Antal aktier | 62,53 mio. |
Højeste/laveste i 52 uger | 972,83 € - 600,21 € |
| Udbytte | Nej |
Beta | -0,02 |
P/E (PE Ratio) | 45,52 |
PEG (PEG Ratio) | 2,38 |
K/I (PB Ratio) | 7,22 |
P/S (PS Ratio) | 13,60 |
Virksomhedsprofil
argenx SE er et bioteknologiselskab, der udvikler forskellige behandlinger til autoimmune sygdomme i USA, Holland, Belgien, Japan, Schweiz, Tyskland og Frankrig. Selskabets vigtigste produktkandidat er efgartigimod til behandling af patienter med myasthenia gravis, immun trombocytopeni, pemphigus vulgaris og kronisk inflammatorisk demyeliniserende polyneuropati i fase III-kliniske forsøg; bulløs pemfigoid og idiopatisk inflammatorisk myopati i fase II/III-kliniske forsøg; og ENHANZE SC i præklinisk undersøgelse. Selskabet udvikler desuden innovationsprogrammer inden for immunologi, herunder cusatuzumab til hæmatologisk kræft samt høj-risiko MDS; ARGX-119, et antistof, der sigter mod muskelspecifik tyrosinkinase-stadiet; ARGX-117 til alvorlige autoimmune indikationer; ARGX-118 til luftvejsinflammation; og ARGX-120 til behandling af autoimmune sygdomme. Derudover omfatter selskabets partnerede produktkandidater ARGX-115 til behandling af kræft; ARGX-112 til behandling af interleukin-22-receptoren; og ARGX-114, et antistof rettet mod MET-receptoren. Selskabet har strategiske partnerskaber med AbbVie S.À.R.L., Zai Lab Limited og LEO Pharma A/S samt et samarbejds- og licensaftale med Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V. og Shire International GmbH. argenx SE blev stiftet i 2008 og har hovedkontor i Breda, Holland.
| Navn | arGEN-X |
| CEO | Karen Massey |
| Hjemsted | Amsterdam,
nh Belgien |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 18.05.2017 |
| Medarbejdere | 1.863 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | ARGX |
Frankfurt | 1AEA.F |
Düsseldorf | 1AEA.DU |
Hamburg | 1AEA.HM |
München | 1AEA.MU |